Chroma Medicine leverages genomic medicine to develop therapeutics able to control gene expression. With the ability to target parts of the genome, the goal is relief for patients suffering from severe illnesses. Chroma Medicine was founded in 2021 by Angelo Lombardo Ph.D., Luigi Naldini Ph.D., David Liu Ph.D., and Jonathan Weissman Ph.D. and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/01/2023 | Series B | $135MM | $xx.xx | $450.56MM | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
51,923,077
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management
|
||||||
11/17/2021 | Series A | $100.7MM | $xx.xx | $254.7MM | Cormorant Asset Management, Casdin Capital, Janus Henderson Investors, Omega Funds, T. Rowe Price Associates, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
47,499,994
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Cormorant Asset Management, Casdin Capital, Janus Henderson Investors, Omega Funds, T. Rowe Price Associates, Wellington Management
|
||||||
05/27/2020 | Series Seed | $26.3MM | $xx.xx | $75.16MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
24,583,572
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|